Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

SINT vs XTNT vs ATEC vs GMED vs OFIX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SINT
Sintx Technologies, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$9M
5Y Perf.-100.0%
XTNT
Xtant Medical Holdings, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$73M
5Y Perf.-57.7%
ATEC
Alphatec Holdings, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.14B
5Y Perf.+69.0%
GMED
Globus Medical, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$10.54B
5Y Perf.+42.6%
OFIX
Orthofix Medical Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$471M
5Y Perf.-65.8%

SINT vs XTNT vs ATEC vs GMED vs OFIX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SINT logoSINT
XTNT logoXTNT
ATEC logoATEC
GMED logoGMED
OFIX logoOFIX
IndustryMedical - DevicesMedical - DevicesMedical - DevicesMedical - DevicesMedical - Devices
Market Cap$9M$73M$1.14B$10.54B$471M
Revenue (TTM)$1M$133M$595M$3.10B$825M
Net Income (TTM)$-17M$2M$-125M$587M$-60M
Gross Margin50.0%62.0%89.6%50.9%69.0%
Operating Margin-8.3%4.8%-9.6%17.2%-4.0%
Forward P/E24.1x16.7x
Total Debt$3M$35M$620M$119M$229M
Cash & Equiv.$4M$6M$161M$526M$82M

SINT vs XTNT vs ATEC vs GMED vs OFIXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SINT
XTNT
ATEC
GMED
OFIX
StockMay 20May 26Return
Sintx Technologies,… (SINT)1000.0-100.0%
Xtant Medical Holdi… (XTNT)10042.3-57.7%
Alphatec Holdings, … (ATEC)100169.0+69.0%
Globus Medical, Inc. (GMED)100142.6+42.6%
Orthofix Medical In… (OFIX)10034.2-65.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: SINT vs XTNT vs ATEC vs GMED vs OFIX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: GMED leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Xtant Medical Holdings, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
SINT
Sintx Technologies, Inc.
The Healthcare Pick

SINT plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
XTNT
Xtant Medical Holdings, Inc.
The Income Pick

XTNT is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.

  • beta 0.67
  • Rev growth 28.4%, EPS growth 107.7%, 3Y rev CAGR 28.5%
  • Lower volatility, beta 0.67, Low D/E 81.8%, current ratio 2.35x
  • Beta 0.67, current ratio 2.35x
Best for: income & stability and growth exposure
ATEC
Alphatec Holdings, Inc.
The Lower-Volatility Pick

ATEC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
GMED
Globus Medical, Inc.
The Long-Run Compounder

GMED carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • 233.8% 10Y total return vs ATEC's 215.7%
  • Better valuation composite
  • 18.9% margin vs SINT's -13.6%
  • +7.6% vs ATEC's -41.0%
Best for: long-term compounding
OFIX
Orthofix Medical Inc.
The Healthcare Pick

Among these 5 stocks, OFIX doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthXTNT logoXTNT28.4% revenue growth vs SINT's -18.3%
ValueGMED logoGMEDBetter valuation composite
Quality / MarginsGMED logoGMED18.9% margin vs SINT's -13.6%
Stability / SafetyXTNT logoXTNTBeta 0.67 vs SINT's 1.94, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)GMED logoGMED+7.6% vs ATEC's -41.0%
Efficiency (ROA)GMED logoGMED11.3% ROA vs SINT's -159.9%, ROIC 8.9% vs -253.2%

SINT vs XTNT vs ATEC vs GMED vs OFIX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SINTSintx Technologies, Inc.
FY 2024
Grant and Contract
56.8%$2M
Product
43.2%$1M
XTNTXtant Medical Holdings, Inc.
FY 2024
Orthobiologics
56.6%$66M
Spinal Implant
42.1%$49M
License Revenue
1.3%$2M
ATECAlphatec Holdings, Inc.
FY 2025
Products And Services
100.0%$764M
GMEDGlobus Medical, Inc.
FY 2024
Spine
93.9%$2.4B
Emerging Technology
6.1%$154M
OFIXOrthofix Medical Inc.
FY 2025
Global Spine
100.0%$688M

SINT vs XTNT vs ATEC vs GMED vs OFIX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLGMEDLAGGINGOFIX

Income & Cash Flow (Last 12 Months)

GMED leads this category, winning 4 of 6 comparable metrics.

GMED is the larger business by revenue, generating $3.1B annually — 2543.6x SINT's $1M. GMED is the more profitable business, keeping 18.9% of every revenue dollar as net income compared to SINT's -13.6%. On growth, GMED holds the edge at +27.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
RevenueTrailing 12 months$1M$133M$595M$3.1B$825M
EBITDAEarnings before interest/tax-$9M$11M$4M$745M$102M
Net IncomeAfter-tax profit-$17M$2M-$125M$587M-$60M
Free Cash FlowCash after capex-$8M$5M$7M$605M-$4M
Gross MarginGross profit ÷ Revenue+50.0%+62.0%+89.6%+50.9%+69.0%
Operating MarginEBIT ÷ Revenue-8.3%+4.8%-9.6%+17.2%-4.0%
Net MarginNet income ÷ Revenue-13.6%+1.3%-21.1%+18.9%-7.3%
FCF MarginFCF ÷ Revenue-6.3%+3.9%+1.2%+19.5%-0.4%
Rev. Growth (YoY)Latest quarter vs prior year-43.3%+19.0%-100.0%+27.0%+1.6%
EPS Growth (YoY)Latest quarter vs prior year+50.2%+123.7%+37.1%+66.7%+61.5%
GMED leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

GMED leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, GMED's 16.9x EV/EBITDA is more attractive than ATEC's 3672.1x.

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
Market CapShares × price$9M$73M$1.1B$10.5B$471M
Enterprise ValueMkt cap + debt − cash$8M$102M$1.6B$10.1B$618M
Trailing P/EPrice ÷ TTM EPS-0.39x-4.33x-7.83x19.89x-5.11x
Forward P/EPrice ÷ next-FY EPS est.24.13x16.70x
PEG RatioP/E ÷ EPS growth rate0.64x
EV / EBITDAEnterprise value multiple3672.06x16.90x
Price / SalesMarket cap ÷ Revenue8.52x0.62x1.49x3.59x0.57x
Price / BookPrice ÷ Book value/share2.27x1.62x31.32x2.34x1.03x
Price / FCFMarket cap ÷ FCF410.02x17.91x
GMED leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

GMED leads this category, winning 8 of 9 comparable metrics.

GMED delivers a 13.0% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-4 for ATEC. GMED carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), GMED scores 9/9 vs XTNT's 2/9, reflecting strong financial health.

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
ROE (TTM)Return on equity-3.7%+3.8%-4.4%+13.0%-13.4%
ROA (TTM)Return on assets-159.9%+1.8%-15.8%+11.3%-7.0%
ROICReturn on invested capital-2.5%-12.8%-12.6%+8.9%-8.6%
ROCEReturn on capital employed-162.4%-17.9%-13.7%+10.4%-9.7%
Piotroski ScoreFundamental quality 0–932694
Debt / EquityFinancial leverage1.11x0.82x17.21x0.03x0.51x
Net DebtTotal debt minus cash-$898,000$29M$459M-$408M$147M
Cash & Equiv.Liquid assets$4M$6M$161M$526M$82M
Total DebtShort + long-term debt$3M$35M$620M$119M$229M
Interest CoverageEBIT ÷ Interest expense-181.30x1.55x-3.29x81.13x-4.97x
GMED leads this category, winning 8 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

GMED leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in GMED five years ago would be worth $10,971 today (with dividends reinvested), compared to $1 for SINT. Over the past 12 months, GMED leads with a +7.6% total return vs ATEC's -41.0%. The 3-year compound annual growth rate (CAGR) favors GMED at 10.2% vs SINT's -79.9% — a key indicator of consistent wealth creation.

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
YTD ReturnYear-to-date-36.5%-30.7%-63.8%-10.7%-21.5%
1-Year ReturnPast 12 months-5.1%-3.2%-41.0%+7.6%-5.4%
3-Year ReturnCumulative with dividends-99.2%-20.0%-49.4%+34.0%-37.4%
5-Year ReturnCumulative with dividends-100.0%-68.9%-46.4%+9.7%-72.5%
10-Year ReturnCumulative with dividends-100.0%-98.0%+215.7%+233.8%-73.0%
CAGR (3Y)Annualised 3-year return-79.9%-7.2%-20.3%+10.2%-14.5%
GMED leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — XTNT and GMED each lead in 1 of 2 comparable metrics.

XTNT is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than SINT's 1.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GMED currently trades 76.9% from its 52-week high vs ATEC's 32.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
Beta (5Y)Sensitivity to S&P 5001.94x0.67x0.74x1.23x1.10x
52-Week HighHighest price in past year$6.78$0.95$23.29$101.40$16.99
52-Week LowLowest price in past year$1.99$0.44$6.85$51.79$10.24
% of 52W HighCurrent price vs 52-week peak+35.4%+54.7%+32.3%+76.9%+68.6%
RSI (14)Momentum oscillator 0–10045.758.633.436.848.4
Avg Volume (50D)Average daily shares traded37K147K3.1M1.1M277K
Evenly matched — XTNT and GMED each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: ATEC as "Buy", GMED as "Buy", OFIX as "Hold". Consensus price targets imply 162.1% upside for ATEC (target: $20) vs 41.5% for GMED (target: $110).

MetricSINT logoSINTSintx Technologie…XTNT logoXTNTXtant Medical Hol…ATEC logoATECAlphatec Holdings…GMED logoGMEDGlobus Medical, I…OFIX logoOFIXOrthofix Medical …
Analyst RatingConsensus buy/hold/sellBuyBuyHold
Price TargetConsensus 12-month target$19.71$110.29$18.00
# AnalystsCovering analysts183617
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+1.5%0.0%0.0%+2.8%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

GMED leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.

Best OverallGlobus Medical, Inc. (GMED)Leads 4 of 6 categories
Loading custom metrics...

SINT vs XTNT vs ATEC vs GMED vs OFIX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is SINT or XTNT or ATEC or GMED or OFIX a better buy right now?

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus -18. 3% for Sintx Technologies, Inc. (SINT). Globus Medical, Inc. (GMED) offers the better valuation at 19. 9x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Alphatec Holdings, Inc. (ATEC) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SINT or XTNT or ATEC or GMED or OFIX?

On forward P/E, Globus Medical, Inc.

is actually cheaper at 16. 7x.

03

Which is the better long-term investment — SINT or XTNT or ATEC or GMED or OFIX?

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +9. 7%, compared to -100. 0% for Sintx Technologies, Inc. (SINT). Over 10 years, the gap is even starker: GMED returned +233. 8% versus SINT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SINT or XTNT or ATEC or GMED or OFIX?

By beta (market sensitivity over 5 years), Xtant Medical Holdings, Inc.

(XTNT) is the lower-risk stock at 0. 67β versus Sintx Technologies, Inc. 's 1. 94β — meaning SINT is approximately 188% more volatile than XTNT relative to the S&P 500. On balance sheet safety, Globus Medical, Inc. (GMED) carries a lower debt/equity ratio of 3% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — SINT or XTNT or ATEC or GMED or OFIX?

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus -18. 3% for Sintx Technologies, Inc. (SINT). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 15. 0% for Alphatec Holdings, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SINT or XTNT or ATEC or GMED or OFIX?

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -1678. 1% for Sintx Technologies, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -1053. 1% for SINT. At the gross margin level — before operating expenses — ATEC leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SINT or XTNT or ATEC or GMED or OFIX more undervalued right now?

On forward earnings alone, Globus Medical, Inc.

(GMED) trades at 16. 7x forward P/E versus 24. 1x for Alphatec Holdings, Inc. — 7. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATEC: 162. 1% to $19. 71.

08

Which pays a better dividend — SINT or XTNT or ATEC or GMED or OFIX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SINT or XTNT or ATEC or GMED or OFIX better for a retirement portfolio?

For long-horizon retirement investors, Alphatec Holdings, Inc.

(ATEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), +215. 7% 10Y return). Sintx Technologies, Inc. (SINT) carries a higher beta of 1. 94 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATEC: +215. 7%, SINT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SINT and XTNT and ATEC and GMED and OFIX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SINT is a small-cap quality compounder stock; XTNT is a small-cap high-growth stock; ATEC is a small-cap high-growth stock; GMED is a mid-cap high-growth stock; OFIX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SINT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 30%
Run This Screen
Stocks Like

XTNT

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 37%
Run This Screen
Stocks Like

ATEC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 53%
Run This Screen
Stocks Like

GMED

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 11%
Run This Screen
Stocks Like

OFIX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 41%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SINT and XTNT and ATEC and GMED and OFIX on the metrics below

Revenue Growth>
%
(SINT: -43.3% · XTNT: 19.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.